Log in
Enquire now
Oligomerix

Oligomerix

A biopharmaceutical company developing therapeutics for Alzheimer's and related neurodegenerative diseases

OverviewStructured DataIssuesContributors

Contents

oligomerix.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Engineering
Engineering
Immunotherapy
Immunotherapy
Technology
Technology
Biology
Biology
Biotechnology
Biotechnology
Biopharmaceutical
Biopharmaceutical
Biomedical engineering
Biomedical engineering
Location
White Plains, New York
White Plains, New York
0
B2X
B2B
B2B
0
CEO
‌
James Moe
0
Founder
‌
Eliot J. Davidowitz
0
‌
James Moe
0
AngelList URL
angel.co/oligomerix
Pitchbook URL
pitchbook.com/profiles.../54310-33
Number of Employees (Ranges)
11 – 500
Email Address
jpasini@oligomerix.com0
Phone Number
+191791240880
Full Address
2 Westchester Park Drive, Suite 208 White Plains, NY 106040
Investors
‌
Durand Venture Associates
‌
Wheatley MedTech Partners
‌
Wheatley Partners
Founded Date
2006
0
Total Funding Amount (USD)
4,800,000
Latest Funding Round Date
May 22, 2013
Latest Funding Type
Series B
Series B
Patents Assigned (Count)
1
Wellfound ID
oligomerix
Country
United States
United States
0
No article content yet.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Oligomerix

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.